Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Translational Therapeutics

Comment on “Redefining cancer research for therapeutic breakthroughs”

British Journal of Cancer (2024)Cite this article

Subjects

I applaud the article by Arseniy Yuzhalin titled ‘Redefining Cancer Research for Therapeutic Breakthroughs’ [1]. The article highlights a number of pivotal areas requiring a system-wide strategic rethinking.

While we as clinicians strive to obtain best possible outcomes for our patients, there is a risk that adhering to a system that has brought significant breakthroughs in cancer may not be the optimum approach moving forward. This is elegantly articulated especially in reference to the reductionism approach which is now well entrenched in cancer science.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yuzhalin AE. Redefining cancer research for therapeutic breakthroughs. Br J Cancer. 2024;130:1078–82. https://doi.org/10.1038/s41416-024-02634-6.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Zang Y, Lee JJ. Adaptive clinical trial designs in oncology. Chin Clin Oncol. 2014;3:49. https://doi.org/10.3978/j.issn.2304-3865.2014.06.04.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Mullins CD, Vandigo J, Zheng Z, Wicks P. Patient-centeredness in the design of clinical trials. Value Health. 2014;17:471–5. https://doi.org/10.1016/j.jval.2014.02.012.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16:29. https://doi.org/10.1186/s12916-018-1017-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mehrara E, Forssell-Aronsson E, Bernhardt P. Objective assessment of tumour response to therapy based on tumour growth kinetics. Br J Cancer. 2011;105:682–6. https://doi.org/10.1038/bjc.2011.276.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kim ES, Atlas J, Ison G, Ersek JL. Transforming Clinical Trial Eligibility Criteria to Reflect Practical Clinical Application. Am Soc Clin Oncol Educ Book. 2016;35:83–90. https://doi.org/10.1200/EDBK_155880.

    Article  CAS  PubMed  Google Scholar 

  7. Johnson K, Gomez A, Burton J, White D, Chakravarty A, Schmid A, et al. Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth. Eur J Cancer. 2019;109:196–203. https://doi.org/10.1016/j.ejca.2018.11.008.

    Article  PubMed  Google Scholar 

  8. Xie X, Li X, Yao W. A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors. Transl Cancer Res. 2021;10:1119–30. https://doi.org/10.21037/tcr-20-2547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tang M, Pearson SA, Simes RJ, Chua BH. Harnessing Real-World Evidence to Advance Cancer Research. Curr Oncol. 2023;30:1844–59. https://doi.org/10.3390/curroncol30020143.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Farah E, Kenney M, Kica A, Haddad P, Stewart DJ, Bradford JP. Beyond Participation: Evaluating the Role of Patients in Designing Oncology Clinical Trials. Curr Oncol. 2023;30:8310–27. https://doi.org/10.3390/curroncol30090603.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yarra Oncology, 6 Davey Drive, Ringwood East, Melbourne, VIC, 3135, Australia

    Prasad Cooray

Authors
  1. Prasad Cooray
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All contributions to this article its from Dr. Prasad Cooray (single author).

Corresponding author

Correspondence to Prasad Cooray.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cooray, P. Comment on “Redefining cancer research for therapeutic breakthroughs”. Br J Cancer (2024). https://doi.org/10.1038/s41416-024-02695-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41416-024-02695-7

Search

Advanced search

Quick links